JNJ Rides Q2 Beat but Sits Right at Resistance Near $253

Johnson & Johnson closed at $253.04 today, up $3.07, or 1.23%, on volume of 10,167,706 shares — slightly above its 20-day average of 9,348,739. That's a solid one-day pop, but the more interesting number is RSI at 48.6: dead center, neither overbought nor oversold, even after a stock that's already up sharply off its 52-week low. This is a name in the middle of digesting a strong quarter, not chasing momentum.

Photo by Monstera Production on Pexels

Recent Price Action

JNJ's move today follows through on strength that's been building for weeks. Shares are sitting just $16.39 below their 52-week high of $269.43 and a full $94.70 above their 52-week low of $158.34 — meaning the stock is trading in the upper third of its annual range. A 1.23% single-day gain on above-average volume suggests real buying interest rather than a low-conviction drift, and it comes on the heels of an earnings report that gave the market something concrete to react to.

Technical Picture: Moving Averages, RSI, and the 52-Week Range

The trend structure here is about as clean as it gets. Price at $253.04 sits above all three key moving averages:

• 20-day SMA: $251.82 — price is just barely above this short-term average, confirming the recent uptrend is intact but not stretched.
• 50-day SMA: $238.32 — a wide ~$14.72 gap above this medium-term average shows sustained momentum over the past couple months.
• 200-day SMA: $221.12 — price is roughly 14.4% above the long-term trendline, a textbook bullish alignment where short-term, medium-term, and long-term averages are stacked in ascending order.

An RSI of 48.6 is the detail that matters most for anyone deciding whether to chase this move. It's neither overbought (above 70) nor oversold (below 30) — it's neutral. That tells you the stock has room to run further before technical indicators would flag it as extended, even though price is already close to its 52-week high. In other words, the rally hasn't gotten ahead of itself yet.

Photo by PublicDomainPictures on Pixabay

The Fundamental Backdrop: A Genuine Beat-and-Raise Quarter

The technical strength lines up with real fundamental news. Johnson & Johnson reported Q2 2026 results with sales of $25.31 billion, up 6.6% reported and above the roughly $25.05 billion analysts had modeled, alongside adjusted EPS of $2.90 versus expectations of $2.85. Innovative Medicine sales came in at $16.38 billion (up 7.8%), with growth led by immunology drug Tremfya and cancer therapy Darzalex offsetting erosion from older, off-patent products. MedTech contributed $8.93 billion, up 4.5%, though heart pump sales softened.

Management didn't just beat — it raised guidance, now targeting roughly $101.1 billion in 2026 revenue and adjusted EPS of $11.68, which would put the company over $100 billion in annual sales for the first time in its 140-year history. That kind of guidance raise, paired with a stock trading near 52-week highs on a still-neutral RSI, is a fairly rare combination: the market has room to keep rewarding the fundamentals without technical indicators screaming caution yet.

Bottom Line

Every moving average here — 20-day, 50-day, and 200-day — is stacked bullishly beneath the current price, volume today confirms real participation rather than a quiet drift, and the fundamental story just got a concrete tailwind from a beat-and-raise quarter with a historic revenue milestone in sight. The one thing to watch is the 52-week high at $269.43 — JNJ hasn't tested that ceiling yet, and how the stock behaves on an approach to that level, especially whether RSI starts pushing toward overbought territory, will say a lot about whether this rally has more room or needs to consolidate first. A pullback toward the 20-day SMA at $251.82 without a break of the 50-day SMA at $238.32 would still keep the broader uptrend intact; a failure to hold the 50-day would be the first real sign the trend is losing steam.

This is not financial advice — always do your own research before making investment decisions.